Lippert Theodor Hermann, Ruoff Hans-Jörg, Volm Manfred
Medical Faculty, University of Tübingen, Tübingen, Germany.
Pharmacology. 2008;81(3):196-203. doi: 10.1159/000112864. Epub 2008 Jan 7.
The frequent resistance of malignant tumors to chemotherapy documents the fact that numerous patients are uselessly traumatized by highly toxic drugs. Investigations into this resistance have shown that many different mechanisms exist which can abolish the antitumor action of chemotherapeutics. So far, no safe method has been found to counteract this resistance. To date, the only way to avoid harm by an ineffective chemotherapeutic is to refrain from its use when resistance to it is detected. The present survey reports on the available assays that diagnose resistance reliably; sensitivity tests are excluded as being unreliable. Resistance assays are still not fully recognized in hospitals, despite the fact that they are able to optimize chemotherapy by eliminating treatment that is ineffective and merely harmful. Since the number of chemotherapeutics will increase enormously in the future, pharmacological cancer treatment cannot dispense with resistance assays.
恶性肿瘤对化疗的频繁耐药表明，许多患者因高毒性药物而受到无谓的创伤。对这种耐药性的研究表明，存在许多不同的机制可以消除化疗药物的抗肿瘤作用。到目前为止，尚未找到安全的方法来对抗这种耐药性。迄今为止，避免无效化疗造成伤害的唯一方法是在检测到耐药性时避免使用该化疗药物。本综述报告了可可靠诊断耐药性的现有检测方法；敏感性测试因不可靠而被排除。尽管耐药性检测能够通过消除无效且仅有害的治疗来优化化疗，但在医院中仍未得到充分认可。由于未来化疗药物的数量将大幅增加，癌症药物治疗离不开耐药性检测。
